gbs-nn/nn2
Vaccineexperimental
Clinical trial activity
7 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Jan 9, 2019 (NCT03807245)
Timeline
Indications
Studied for
Mechanism of action
- Streptococcus sp. group BImmunity, active
Streptococcus sp. group B immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06592586 | Phase 2/Phase 3 (Phase 3) | Jan 20, 2025 | Minervax ApS |
| NCT06494475 | Phase 2/Phase 3 (Phase 3) | Dec 17, 2024 | Minervax ApS |
| NCT05782179 | Phase 1 | Mar 1, 2023 | IQVIA, Minervax ApS, ProPharma |
| NCT05154578 | Phase 2 | Jan 31, 2022 | Minervax ApS, ProPharma |
| NCT05005247 | Phase 1 | Aug 17, 2021 | Minervax ApS, ProPharma |
| NCT04596878 | Phase 2 | Nov 19, 2020 | European and Developing Countries Clinical Trials Partnership (EDCTP), Minervax ApS, University of London |
| NCT03807245 | Phase 1 | Jan 9, 2019 | Minervax ApS, Simbec-Orion |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Minervax ApS | For profit | 7 | 7 | 3 | 2019 |
| ProPharma | For profit | 3 | 0 | 2 | 2021 |
| European and Developing Countries Clinical Trials Partnership (EDCTP) | Academic/Hospital | 1 | 0 | 1 | 2020 |
| IQVIA | For profit | 1 | 0 | 1 | 2023 |
| Simbec-Orion | For profit | 1 | 0 | 1 | 2019 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2020 |
6 organizations
Page 1 / 1